VitaDX: Artificial intelligence dedicated to the early detection of cancers Using image processing and machine learning algorithms, VitaDX, based on fluorescence imaging research at the Orsay Institute of Molecular Sciences, will automate early bladder cancer detection.
Thursday June 15th, 2017
Tuesday June 13th, 2017
VitaDX quoted in Les Echos for its second fundraising: "VitaDX wants to strengthen the early diagnosis of bladder cancer"
Monday June 12th, 2017
VitaDX is very pleased to announce the signing of a partnership with Cerba Healthcare as part of the validation of the VisioCyt® test for early diagnosis of bladder cancer.
Tuesday June 6th, 2017
VitaDX has just closed its second fundraising € 1.6 million with two investment funds Go Capital and Auriga Partners as well as private investors.